Dobrý den, našla jsem akorát v angličtině odborný článek - studii, jehož závěrečnou část tady přeposílám. Jinak bych určitě od lékařů požadovala veškěrá možná vyšetření, byť by byla nehrazena pojišťovnou a nejspíš za sebe bych to riskla a děťátko donosila, podle článku riziko potratu vyšší není a je ale třeba pohlídat co nejdřív těhotenskou cukrovku,zda se neobjeví!Tak přeji pevné nervy a nebojte,dobře to dopadne!Hanka(mám 3,5měsíční dceru,od 30.týdne mi lékaři řekli,že je moc malá a že je možné,že nebude vše OK,taky jsem si prožila své a nakonec měla 2,6kg a až na reflux v pohodě).Results The proportion of liveborn infants with major structural anomalies was similar in the two groups (3.6% vs. 1.0%, relative risk (RR) 3.59; 95% confidence interval (CI) 0.61, 21.10), as was the proportion of infants with 3 minor anomalies (11.7% vs. 7.6%, RR 1.53; 95% CI 0.61, 3.82). Furthermore, no pattern of malformation was identified. There were no significant differences between the groups in spontaneous pregnancy loss (6.1% vs. 8.2%, P = 0.65) or premature delivery (8.6% vs. 7.7%, P = 0.95). Birth weight and head circumference were significantly increased in the exposed group; however, these differences were not associated with anorexiant use itself. The rate of gestational diabetes was significantly increased in pregnant women who took phentermine/fenfluramine during the first trimester of pregnancy. Conclusions Although it is not possible from this study to rule out weak to moderate associations, the lack of an increased risk of spontaneous pregnancy loss, and major or minor anomalies in the offspring of women who took phentermine/fenfluramine at the recommended daily dose during the first trimester of pregnancy is reassuring. Teratology 65:125-130, 2002. © 2002 Wiley-Liss, Inc.